Ipamorelin 5mg + Tesamorelin 5mg (10mg Blend Vial) Dosage Protocol
Contents
Quickstart Highlights
This blend combines tesamorelin, a synthetic GHRH analog, with ipamorelin, a selective ghrelin mimetic (growth hormone secretagogue). When administered together, GHRH analogs and ghrelin mimetics produce synergistic GH pulses[1][2]. The FDA‑approved tesamorelin dose is 2 mg SC daily[3], while ipamorelin is commonly studied at 100–300 mcg SC daily[4]. This educational protocol presents a once‑daily subcutaneous approach with gradual titration using a 1:1 blend ratio.
- Reconstitute: Add 3.0 mL bacteriostatic water to the 10 mg vial → ~3.33 mg/mL total (1.67 mg/mL each peptide).
- Typical daily range: 250–2000 mcg tesamorelin + 125–1000 mcg ipamorelin (gradual titration).
- Easy measuring: At 3.33 mg/mL total, 1 unit = 0.01 mL ≈ 16.7 mcg of each peptide on a U‑100 insulin syringe.
- Storage: Lyophilized: refrigerate at 2–8 °C (35.6–46.4 °F); after reconstitution, use immediately or refrigerate and use within 24–48 hours[5].
Dosing & Reconstitution Guide
Standard / Gradual Approach (3 mL = ~3.33 mg/mL total)
Route: Subcutaneous (SC) | Frequency: Once daily
| Week | Tesamorelin Dose | Ipamorelin Dose | Units (mL) |
|---|---|---|---|
| Weeks 1–2 | 250 mcg (0.25 mg) | 125 mcg (0.125 mg) | 23 units (0.23 mL) |
| Weeks 3–4 | 500 mcg (0.5 mg) | 250 mcg (0.25 mg) | 45 units (0.45 mL) |
| Weeks 5–6 | 1000 mcg (1.0 mg) | 500 mcg (0.5 mg) | 90 units (0.90 mL) |
| Weeks 7–10 | 1500 mcg (1.5 mg) | 750 mcg (0.75 mg) | 135 units (1.35 mL) |
| Weeks 11–16 | 2000 mcg (2.0 mg) | 1000 mcg (1.0 mg) | 180 units (1.80 mL) |
Note: The 1:1 blend ratio means tesamorelin and ipamorelin are present in equal amounts per mL. At 3.0 mL reconstitution: 1 mL = 1.67 mg tesamorelin + 1.67 mg ipamorelin. Higher‑volume injections (≥1.0 mL) may be split across two sites if preferred for comfort.
Reconstitution Steps
- Draw 3.0 mL bacteriostatic water with a sterile syringe.
- Inject slowly down the vial wall; avoid foaming.
- Gently swirl/roll until dissolved (do not shake).
- Label and refrigerate at 2–8 °C (35.6–46.4 °F), protected from light; use within 24–48 hours[5].
Important: This guide is for educational purposes only and is not medical advice. For research use only. Not for human consumption.
Supplies Needed
Plan based on an 8–16 week daily protocol with gradual titration.
- Peptide Vials (Tesamorelin 5 mg + Ipamorelin 5 mg, 10 mg blend each):
- 8 weeks ≈ 10 vials
- 12 weeks ≈ 19 vials
- 16 weeks ≈ 31 vials
- Insulin Syringes (U‑100):
- Per week: 7 syringes (1/day)
- 8 weeks: 56 syringes
- 12 weeks: 84 syringes
- 16 weeks: 112 syringes
- Bacteriostatic Water (10 mL bottles): Use ~3.0 mL per vial for reconstitution.
- 8 weeks (10 vials): 30 mL → 3 × 10 mL bottles
- 12 weeks (19 vials): 57 mL → 6 × 10 mL bottles
- 16 weeks (31 vials): 93 mL → 10 × 10 mL bottles
- Alcohol Swabs: One for the vial stopper + one for the injection site each day.
- Per week: 14 swabs (2/day)
- 8 weeks: 112 swabs → recommend 2 × 100‑count boxes
- 12 weeks: 168 swabs → recommend 2 × 100‑count boxes
- 16 weeks: 224 swabs → recommend 3 × 100‑count boxes
![insulin[1]](https://peptidedosing.ca/wp-content/uploads/2026/01/insulin1-178x178.webp "insulin[1]")
![Bacteriostatic-Water-Bottle[1]](https://peptidedosing.ca/wp-content/uploads/2026/01/Bacteriostatic-Water-Bottle1-178x178.webp "Bacteriostatic-Water-Bottle[1]")
![EasyTouch_Alcohol_Pads[1]](https://peptidedosing.ca/wp-content/uploads/2026/01/EasyTouch_Alcohol_Pads1-178x178.avif "EasyTouch_Alcohol_Pads[1]")
Protocol Overview
Concise summary of the once‑daily regimen.
- Goal: Support pulsatile GH release through dual GHRH + ghrelin pathway stimulation[1][2].
- Schedule: Daily subcutaneous injections for 8–16 weeks.
- Dose Range: Tesamorelin 250–2000 mcg + ipamorelin 125–1000 mcg daily with gradual titration.
- Reconstitution: 3.0 mL per 10 mg vial (~3.33 mg/mL total) for accurate unit measurements.
- Storage: Lyophilized refrigerated 2–8 °C; reconstituted use immediately or within 24–48 hours.
Dosing Protocol
Suggested daily titration approach.
- Start: 250 mcg tesamorelin + 125 mcg ipamorelin daily; increase every 2 weeks.
- Target: 1500–2000 mcg tesamorelin + 750–1000 mcg ipamorelin by Weeks 7–16.
- Frequency: Once per day (subcutaneous).
- Cycle Length: 8–16 weeks.
- Timing: Evening or bedtime administration may align with natural GH secretion patterns[4]; rotate injection sites.
Storage Instructions
Proper storage preserves peptide quality.
- Lyophilized: Store at 2–8 °C (35.6–46.4 °F) in dry, dark conditions; may be kept at ≤25 °C (77 °F) up to 3 months after dispensing[5].
- Reconstituted: Inject immediately after reconstitution; if stored, refrigerate and use within 24–48 hours; do not freeze[5].
- Allow vials to reach room temperature before opening to reduce condensation uptake.
Important Notes
Practical considerations for consistency and safety.
- Use new sterile insulin syringes; dispose in a sharps container.
- Rotate injection sites (abdomen, thighs, upper arms) to reduce local irritation[5][6].
- Inject slowly; wait a few seconds before withdrawing the needle.
- Document daily dose and site rotation to maintain consistency.
- Higher‑volume injections (≥1.0 mL) may be split between two sites for comfort.
How This Works
Tesamorelin is a synthetic 44‑amino‑acid GHRH analog that stimulates pituitary GH release[3]. Ipamorelin is a pentapeptide ghrelin mimetic that acts on the GHS‑R1a receptor, selectively stimulating GH secretion without significantly affecting cortisol, prolactin, or ACTH[4][7]. Combined GHRH + GHRP/ghrelin‑mimetic administration produces synergistic, amplified GH pulses compared to either agent alone[1][2]. Human pharmacokinetic studies show ipamorelin achieves peak GH release approximately 40 minutes post‑dose[8].
Potential Benefits & Side Effects
Observations from preclinical and clinical literature.
- Enhanced pulsatile GH secretion through dual‑pathway stimulation[1][2].
- Tesamorelin (2 mg/day) demonstrated reductions in trunk fat and visceral adipose tissue in HIV‑associated lipodystrophy trials[3][9].
- Ipamorelin shows high GH selectivity with minimal impact on cortisol or other hormones[4][7].
- Common adverse events with tesamorelin include injection‑site reactions (erythema, pruritus), arthralgia, and peripheral edema[5][9].
- Ipamorelin is generally well tolerated; transient flushing or headache may occur[7].
Lifestyle Factors
Complementary strategies for best outcomes.
- Pair with a balanced, protein‑forward diet tailored to energy needs.
- Combine resistance training and aerobic activity to reinforce metabolic adaptations.
- Prioritize sleep and stress management to support adherence and recovery.
- Evening dosing may align with natural nocturnal GH secretion patterns.
Injection Technique
General subcutaneous guidance from clinical best‑practice resources[6].
- Clean the vial stopper and skin with alcohol; allow to dry.
- Pinch a skinfold; insert the needle at 45–90° into subcutaneous tissue[6][10].
- Do not aspirate for subcutaneous injections; inject slowly and steadily[6].
- Rotate sites systematically (abdomen, thighs, upper arms) to avoid lipohypertrophy[5][11].
Recommended Source
We recommend Amino Labs for high-purity BPC-157 + TB-500 (20 mg Blend).
Why Amino Labs?
- High-purity (≥99% HPLC), third-party-tested lots with batch COAs.
- Consistent, ISO-aligned handling and documentation.
- Reliable fulfillment to maintain cold-chain integrity.
Important Note
This content is intended for therapeutic educational purposes only and does not constitute medical advice, diagnosis, or treatment.
References
— GHRH + GHRP synergy; dual pathway GH stimulation mechanisms
— Synergistic amplification of GH release with combined GHRH and ghrelin mimetics
— Synthetic GHRH analog; recommended dose 2 mg SC daily for HIV lipodystrophy
— High GH potency and selectivity; no cortisol/ACTH effect
— SC abdomen injection; rotate sites; storage and reconstitution guidance
— Subcutaneous injection technique (45° angle, pinch skin, no aspiration)
— Potent and specific GH release without affecting cortisol, prolactin, or FSH/LH
— Human GH release peaked ~0.67 h post-dose
— Phase 3 trials demonstrating visceral fat reduction with tesamorelin
— General subcutaneous route guidance (angle/site)
— Asepsis, preparation, and administration guidance
— Pharmacologic considerations of the subcutaneous route
— Comprehensive review of tesamorelin pharmacology and clinical use